Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

Shanghai Henlius Biotech, Inc.
上海復宏漢霖生物技術股份有限公司
(A joint stock company incorporated in the People's Republic of China with limited liability)
(Stock code: 2696)

POLL RESULTS OF THE RESOLUTIONS PROPOSED AT THE 2025 THIRD EXTRAORDINARY GENERAL MEETING HELD ON FRIDAY, 29 AUGUST 2025 COMPOSITION OF COMMITTEES OF THE BOARD RE-APPOINTMENT OF CHAIRMAN OF THE BOARD AND CHAIRMAN OF THE BOARD OF SUPERVISORS AND RE-APPOINTMENT OF CHIEF EXECUTIVE OFFICER

The board (the "**Board**") of directors (the "**Directors**") of Shanghai Henlius Biotech, Inc. (the "**Company**", together with its subsidiaries, the "**Group**") is pleased to announce the poll results of the 2025 third extraordinary general meeting (the "**EGM**") held at Conference Room, 10th Floor, B8 Building, No. 188 Yizhou Road, Xuhui District, Shanghai, PRC at 4:00 p.m. on Friday, 29 August 2025.

References are made to the notice and the circular (the "**Circular**") of the Company both dated 12 August 2025 and the announcement of the Company dated 15 August 2025 in relation to the EGM. Unless the context otherwise requires, capitalised terms used in this announcement shall have the same meanings as those defined in the Circular.

EGM

As at the date of the EGM, the total number of the issued shares of the Company (the "**Shares**") was 543,494,853 Shares, comprising 380,066,312 Unlisted Shares and 163,428,541 H Shares, all of which entitled the holders (or authorised representatives) to attend and vote on the resolutions proposed at the EGM (the "**Resolutions**"). Shareholders or authorised representatives holding an aggregate of 396,406,934 Shares with voting rights, representing approximately 72.936649% of the total number of the Shares with voting rights of the Company were present at the EGM. All Directors attended the EGM.

To the best of the Directors' knowledge, information and belief, having made all reasonable enquiries, no Shareholder was required to abstain from voting on the Resolutions under the Listing Rules, and there was no Share entitling the holder to attend the EGM and abstain from voting in favour of the Resolutions under Rule 13.40 of the Listing Rules. No Shareholder had stated the intention in the Circular to vote against or to abstain from voting on the Resolutions.

Pursuant to the Listing Rules and the articles of association of the Company (the "**Articles of Association**"), Computershare Hong Kong Investor Services Limited, representatives from the Shareholders and a member of the Board of Supervisors of the Company acted as the scrutineers for vote tabulation at the EGM.

The EGM was convened in compliance with the requirements of the Company Law of the PRC and the Articles of Association. Mr. Wenjie Zhang, the chairman of the Board of the Company, acted as the chairman of the EGM.

POLL RESULTS OF THE EGM

The poll results in respect of the Resolutions are as follows:

Ordinary Resolutions			**Number of valid votes and percentage of total number of votes (%)**		
			For	**Against**	**Abstain**
1.	To consider and approve the resolutions in relation to the re-appointment and appointment of Directors of the fourth session of the Board.				
	1.1	the re-appointment of Dr. Jun Zhu, being the current executive Director, as the executive Director of the fourth session of the Board;	396,247,345 (99.959741%)	109,589 (0.027646%)	50,000 (0.012613%)
	1.2	the re-appointment of Mr. Wenjie Zhang, being a current non-executive Director, as a non-executive Director of the fourth session of the Board;	394,920,890 (99.625122%)	1,436,044 (0.362265%)	50,000 (0.012613%)
	1.3	the re-appointment of Mr. Qiyu Chen, being a current non-executive Director, as a non-executive Director of the fourth session of the Board;	395,545,912 (99.782793%)	811,022 (0.204594%)	50,000 (0.012613%)
	1.4	the re-appointment of Ms. Xiaohui Guan, being a current non-executive Director, as a non-executive Director of the fourth session of the Board;	394,590,635 (99.541809%)	1,766,299 (0.445578%)	50,000 (0.012613%)
	1.5	the re-appointment of Dr. Xingli Wang, being a current non-executive Director, as a non-executive Director of the fourth session of the Board;	396,141,245 (99.932976%)	215,689 (0.054411%)	50,000 (0.012613%)
	1.6	the re-appointment of Mr. Tak Young So, being a current independent non-executive Director, as an independent non-executive Director of the fourth session of the Board;	396,321,734 (99.978507%)	35,200 (0.008880%)	50,000 (0.012613%)

Ordinary Resolutions			Number of valid votes and percentage of total number of votes (%)		
			For	Against	Abstain
	1.7	the re-appointment of Dr. Lik Yuen Chan, being a current independent non-executive Director, as an independent non-executive Director of the fourth session of the Board;	396,321,734 (99.978507%)	35,200 (0.008880%)	50,000 (0.012613%)
	1.8	the re-appointment of Dr. Ruilin Song, being a current independent non-executive Director, as an independent non-executive Director of the fourth session of the Board;	395,605,680 (99.797871%)	751,254 (0.189516%)	50,000 (0.012613%)
	1.9	the appointment of Mr. Yuqing Chen as a non-executive Director of the fourth session of the Board;	396,138,245 (99.932219%)	218,689 (0.055168%)	50,000 (0.012613%)
	1.10	the appointment of Dr. Yi Liu as a non-executive Director of the fourth session of the Board;	396,138,245 (99.932219%)	218,689 (0.055168%)	50,000 (0.012613%)
	1.11	the appointment of Mr. Yihao Zhang as an independent non-executive Director of the fourth session of the Board.	396,356,934 (99.987387%)	0 (0.000000%)	50,000 (0.012613%)
	As more than half of the votes were cast in favour of resolutions 1.1 to 1.11, such resolutions were duly passed as ordinary resolutions.				
2.	To consider and approve the resolutions in relation to the re-appointment of Shareholder representative Supervisors of the fourth session of the Board of Supervisors:				
	2.1	the re-appointment of Ms. Rongli Feng, being a current Shareholder representative Supervisor, as a Shareholder representative Supervisor of the Company;	396,356,934 (99.987387%)	0 (0.000000%)	50,000 (0.012613%)
	2.2	the re-appointment of Mr. Deli Kong, being a current Shareholder representative Supervisor, as a Shareholder representative Supervisor of the Company.	395,760,169 (99.836843%)	596,765 (0.150544%)	50,000 (0.012613%)
	As more than half of the votes were cast in favour of resolutions 2.1 to 2.2, such resolutions were duly passed as ordinary resolutions.				

Ordinary Resolutions		Number of valid votes and percentage of total number of votes (%)		
		For	Against	Abstain
3.	To consider and approve the resolution in relation to the proposed amendments to the Rules of Procedures for the General Meeting, which will take effect immediately upon approval at the EGM.	396,356,934 (99.987387%)	0 (0.000000%)	50,000 (0.012613%)
	As more than half of the votes were cast in favour of this resolution, the resolution was duly passed as an ordinary resolution.			
4.	To consider and approve the resolution in relation to the proposed amendments to the Rules of Procedures for the Board, which will take effect immediately upon approval at the EGM.	396,356,934 (99.987387%)	0 (0.000000%)	50,000 (0.012613%)
	As more than half of the votes were cast in favour of this resolution, the resolution was duly passed as an ordinary resolution.			
5.	To consider and approve the resolution in relation to the proposed amendments to the Rules of Procedures for the Board of Supervisors, which will take effect immediately upon approval at the EGM.	396,356,934 (99.987387%)	0 (0.000000%)	50,000 (0.012613%)
	As more than half of the votes were cast in favour of this resolution, the resolution was duly passed as an ordinary resolution.			
6.	To consider and approve the resolution in relation to the proposed amendment to the Regulations for Preventing the Misappropriation of the Company's Funds by the Controlling Shareholder and its Related Parties/Connected Persons, which will take effect immediately upon approval at the EGM.	396,356,934 (99.987387%)	0 (0.000000%)	50,000 (0.012613%)
	As more than half of the votes were cast in favour of this resolution, the resolution was duly passed as an ordinary resolution.			
7.	To consider and approve the resolution in relation to the proposed amendment to the Profit Distribution Management System, which will take effect immediately upon approval at the EGM.	396,356,934 (99.987387%)	0 (0.000000%)	50,000 (0.012613%)
	As more than half of the votes were cast in favour of this resolution, the resolution was duly passed as an ordinary resolution.			

Special Resolution		Number of valid votes and percentage of total number of votes (%)		
		For	Against	Abstain
8.	To consider and approve the resolution in relation to the proposed amendments to the Articles of Association, which will take effect immediately upon approval at the EGM.	396,356,934 (99.987387%)	0 (0.000000%)	50,000 (0.012613%)
	As more than two-thirds of the votes were cast in favour of this resolution, the resolution was duly passed as a special resolution.			

COMPOSITION OF COMMITTEES OF THE BOARD

The Board is pleased to announce the composition of each committee of the fourth session of the Board of the Company:

(1) Mr. Tak Young So, Dr. Lik Yuen Chan and Ms. Xiaohui Guan are re-appointed as members of the Audit Committee of the Board (the "**Audit Committee**"), and Mr. Tak Young So is re-appointed as the chairman of the Audit Committee.

(2) Mr. Yihao Zhang is appointed, and Mr. Wenjie Zhang, Ms. Xiaohui Guan, Mr. Tak Young So and Dr. Ruilin Song are re-appointed as members of the Nomination Committee of the Board (the "**Nomination Committee**"), and Mr. Wenjie Zhang is re-appointed as the chairman of the Nomination Committee.

(3) Mr. Yuqing Chen is appointed, and Dr. Ruilin Song and Dr. Lik Yuen Chan are re-appointed as members of the Remuneration Committee of the Board (the "**Remuneration Committee**"), and Dr. Ruilin Song is re-appointed as the chairman of the Remuneration Committee.

(4) Mr. Yuqing Chen and Dr. Yi Liu is appointed, and Mr. Wenjie Zhang, Dr. Jun Zhu, Mr. Qiyu Chen, Dr. Xingli Wang, Mr. Tak Young So and Dr. Ruilin Song are re-appointed as members of the Strategy Committee of the Board (the "**Strategy Committee**"), and Mr. Wenjie Zhang is re-appointed as the chairman of the Strategy Committee.

(5) Dr. Lik Yuen Chan, Mr. Tak Young So, Dr. Ruilin Song, Mr. Wenjie Zhang and Dr. Jun Zhu are re-appointed as members of the Environmental, Social and Governance Committee of the Board (the "**Environmental, Social and Governance Committee**"), and Dr. Lik Yuen Chan is re-appointed as the chairman of the Environmental, Social and Governance Committee.

Mr. Yifang Wu, Mr. Deyong Wen and Dr. Guoping Zhao cease to serve as members of the related committees of the Board due to their retirement as non-executive Directors or an independent non-executive Director of the Company. The appointments and retirements in relation to the committees of the Board shall take effect from 29 August 2025.

RE-APPOINTMENT OF CHAIRMAN OF THE BOARD

The Board is pleased to announce that Mr. Wenjie Zhang has been re-appointed as the chairman of the fourth session of the Board with effect from 29 August 2025 until the expiry of the term of the fourth session of the Board.

RE-APPOINTMENT OF CHAIRMAN OF THE BOARD OF SUPERVISORS

The Board is pleased to announce that Ms. Rongli Feng has been re-appointed as the chairman of the fourth session of the Board of Supervisors of the Company with effect from 29 August 2025 until the expiry of the term of the fourth session of the Board of Supervisors.

RE-APPOINTMENT OF CHIEF EXECUTIVE OFFICER

The Board is pleased to announce that Dr. Jun Zhu ("**Dr. Zhu**") has been re-appointed as the chief executive officer of the Company with effect from 29 August 2025 until the expiry of the term of the fourth session of the Board. Dr. Zhu, as the chief executive officer of the Company, will continue to lead the management in overseeing the daily operation of the Company, and will be accountable to the Board.

INFORMATION REQUIRED TO BE DISCLOSED PURSUANT TO RULE 13.51(2) OF THE HONG KONG LISTING RULES

Biography of Dr. Jun Zhu

Dr. Jun Zhu (朱俊), aged 47, has served as the chief executive officer of the Company since July 2023 and has served as an executive Director of the Company since August 2023. Dr. Zhu joined the Group in January 2021 and has been the senior vice president and chief medical officer of Shanghai Henlius Biopharmaceutical Co., Ltd.* (上海復宏漢霖生物製藥有限公司), and the senior vice president and chief medical officer, the chief financial officer and the president of the Company. Dr. Zhu holds directorship and managerial positions in certain other subsidiaries of the Company.

Prior to joining the Group, Dr. Zhu served as the internal medicine physician in Huashan Hospital affiliated to Fudan University in Shanghai from July 2001 to October 2003; the project manager of IQVIA Holdings Inc. from August 2003 to June 2005; the general manager (Greater China) of Omnicare Clinical Research Inc. from March 2008 to July 2012; the global vice-president of IQVIA Holdings Inc. from August 2012 to January 2017; and the founder and chief executive officer of Shanghai PPC Biopharmaceutical Technology Co., Ltd.* (上海百利佳生醫藥科技有限公司) from February 2018 to August 2020. Dr. Zhu obtained a bachelor's degree in clinical medicine from Fudan University (復旦大學) in the PRC in July 2001, an EMBA degree from Cheung Kong Graduate School of Business (長江商學院) in the PRC in September 2018, and a doctoral degree in health management from University of Montpellier in France in June 2024.

The remuneration of Dr. Zhu as the chief executive officer of the Company shall be determined based on his duties and responsibilities and the operation and financial performance of the Company, and is subject to the approval by the Board. The Company will disclose the remuneration of Dr. Zhu during the reporting period in the annual report.

As at the date of this announcement, Dr. Zhu holds 750,000 Share options and 750,000 restricted share units (RSUs) granted under the Share option scheme and the RSU scheme of the Company. In addition, Dr. Zhu indirectly holds 50,000 Shares of the Company through Dr. JZ Limited, which is under his control.

As at the date of this announcement, save as disclosed above, Dr. Zhu has confirmed that he (i) did not hold any directorships or supervisor positions in other publicly listed companies in the last three years nor take up any posts in any group members of the Company; (ii) does not have any relationship with any Directors, Supervisors, senior management, substantial Shareholders or controlling Shareholders of the Company; and (iii) does not have any interests in the Shares or underlying Shares of the Company and its associated corporations within the meaning of Part XV of the SFO.

Save as disclosed in this announcement, there are no other matters relating to the appointment of Dr. Zhu that need to be brought to the attention of the Shareholders of the Company, nor is there any other information to be disclosed pursuant to any of the requirements of Rule 13.51(2) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited.

On behalf of the Board
Shanghai Henlius Biotech, Inc.
Wenjie Zhang
Chairman

Hong Kong, 29 August 2025

As at the date of this announcement, the board of directors of the Company comprises Mr. Wenjie Zhang as the chairman and non-executive director, Dr. Jun Zhu as the executive director, Mr. Qiyu Chen, Mr. Yuqing Chen, Ms. Xiaohui Guan, Dr. Yi Liu and Dr. Xingli Wang as the non-executive directors, and Mr. Tak Young So, Dr. Lik Yuen Chan, Dr. Ruilin Song and Mr. Yihao Zhang as the independent non-executive directors.